Active	Status	Sponsor type	Region	Phase	Filter
1 Active 6 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
fasoracetam (NB-001) / Nobias Therap
NCT05290493: NB-001 in Children and Adolescents With 22q11 Deletion Syndrome	Completed	2	37	Canada, US	NB-001, fasoracetam monohydrate, (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one monohydrate, Placebo	Nobias Therapeutics, Inc.	22q11 Deletion Syndrome	06/23	06/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
fasoracetam (NB-001) / Nobias Therap
NCT05290493: NB-001 in Children and Adolescents With 22q11 Deletion Syndrome	Completed	2	37	Canada, US	NB-001, fasoracetam monohydrate, (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one monohydrate, Placebo	Nobias Therapeutics, Inc.	22q11 Deletion Syndrome	06/23	06/23